Freeline Therapeutics Holdings plc (FRLN)의 가격은 얼마입니까?

Freeline Therapeutics Holdings plc (FRLN)의 가격은 $6.48입니다.

Freeline Therapeutics Holdings plc (FRLN)의 시가 총액은 무엇입니까?

Freeline Therapeutics Holdings plc (FRLN)의 시가 총액은 $15.41M입니다.

Freeline Therapeutics Holdings plc (FRLN) PER

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

연도	P/E 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/E 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/E 비율	P/E 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
CSL Limited CSL.AX	32.46	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	18.38	-	BE

회사

P/E 비율

P/E 비율 차이

국가